Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Poly MedicureNSE:POLYMED -0.81%100 ROC (Joel Greenblatt) % is 23.11% as of Jun. 2026, which is 21% below its 10-year median of 29.29. GuruFocus rates NSE:POLYMED with a GF Score™ of 100/100 and a GF Value™ of ₹2,428.11 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 836 Medical Devices & Instruments companies, Poly Medicure ranks better than 73.44% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Poly Medicure's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 23.11%.
The historical rank and industry rank for Poly Medicure's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:POLYMED'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 23.28 Med: 29.29 Max: 33.9
Current: 23.58
During the past 13 years, Poly Medicure's highest ROC (Joel Greenblatt) % was 33.90%. The lowest was 23.28%. And the median was 29.29%.
NSE:POLYMED's ROC (Joel Greenblatt) % is ranked better than 73.44% of 836
companies
in the Medical Devices & Instruments industry
Industry Median: 4.86
vs NSE:POLYMED: 23.58
Poly Medicure's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -4.30% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Poly Medicure ROC (Joel Greenblatt) % Related Terms
Poly Medicure ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Poly Medicure's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:POLYMED vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Poly Medicure's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poly Medicure ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Poly Medicure's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Poly Medicure's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 23.11% mean?
Poly Medicure (NSE:POLYMED) has a ROC (Joel Greenblatt) % of 23.11% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Poly Medicure and its competitors. This is 21% below median its historical median of 29.29. Over the past decade, Poly Medicure's ROC (Joel Greenblatt) % has ranged from 23.28 to 33.90. According to the industry distribution chart, Poly Medicure ranks #222 out of 836 companies in the Medical Devices & Instruments industry, placing it in the top 26.6%.
Is Poly Medicure's ROC (Joel Greenblatt) % too high?
Poly Medicure's current ROC (Joel Greenblatt) % of 23.11% is 21% below median its 10-year median of 29.29. Over the past 10 years, this metric has ranged from a low of 23.28 to a high of 33.90. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.86. Poly Medicure's value of 23.11% is 375.5% above this industry median. Based on the distribution chart, Poly Medicure ranks #222 out of 836 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Poly Medicure has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Poly Medicure's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Poly Medicure ranks #222 out of 836 companies for ROC (Joel Greenblatt) %. This puts Poly Medicure in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.86. Poly Medicure's value of 23.11% is 375.5% above this benchmark. Historically, Poly Medicure's own ROC (Joel Greenblatt) % has ranged from 23.28 to 33.90 over the past decade. While the company's 10-year median is 29.29 vs. the industry median of 4.86, Poly Medicure has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.86, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poly Medicure's current ROC (Joel Greenblatt) % of 23.11% is 375.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Poly Medicure and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poly Medicure's current ROC (Joel Greenblatt) % is 23.11%, which is 21% below median its own 10-year median of 29.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poly Medicure stock overvalued right now?
Based on GuruFocus' analysis, Poly Medicure (NSE:POLYMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,428.11, compared to a current price of ₹1,770.30 — trading 27.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 23.11%, which is 21% below median its 10-year median of 29.29 and 375.5% above the Medical Devices & Instruments industry median of 4.86. Poly Medicure's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Poly Medicure (NSE:POLYMED), the current ROC (Joel Greenblatt) % is 23.11% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poly Medicure (NSE:POLYMED) Overvalued in 2026?
Based on GuruFocus' analysis, Poly Medicure stock appears to be undervalued.
The current stock price of ₹1,770.30 is trading 27.1% below its estimated GF Value™ of ₹2,428.11.
GuruFocus considers Poly Medicure to be Modestly Undervalued.
Key valuation signals for NSE:POLYMED:
ROC (Joel Greenblatt) %: 23.11% (21% below median its 10-year median of 29.29)
GF Value™: ₹2,428.11 vs. price of ₹1,770.30 (27.1% below fair value)
Industry Position: 375.5% above the Medical Devices & Instruments median (#222 of 836)
No single metric tells the full story. See the NSE:POLYMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
100GF Score
Get the complete analysis for NSE:POLYMED
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:POLYMED has been successfully added to your 
